Stock·NASDAQ·Industrials
Honeywell International Inc. (HON)
- Market cap
- $67.00B
- P/E
- 7.65
- Street target
- $262.00median of 24 analysts
- 52-week range
- $186.76 $252.00
The short version
Where HON stands today, in four lines, and what CleaRank Financial AI makes of it.
HON at a glance
Honeywell International Inc. (HON): Hold, 57/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($214.52 and $223.97).
- Earnings HON beat estimates in 8 of its last 8 quarters, yet fell the next day after 7 of those beats.
- Insiders Insiders sold $20.7M and made no open-market purchases over the last 18 months.
- Valuation P/E of 7.7 against 34.0 for the Industrials sector: a discount to peers (-77%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Honeywell International Inc. (HON) Hold, with a model score of 57/100.
Valuation lifts the score most: the P/E of 7.65 is 77.5% below the sector median (a discount to peers) and the P/S of 1.75 is 56.3% below the sector median. The trend holds it back most: the price is 5.61% below its 200-day average and 1.45% below its 50-day average, and the 50-day average is 4.22% below the 200-day. The 50-day average stands at $214.52 and the 200-day at $223.97. Over the past year the price rose 10.40%.
Only on CleaRank
Figures we compute ourselves from HON's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $211.41 is 1.5% below the 50-day simple moving average of $214.52.Price above its 200-day average ›
The price is 5.6% below the 200-day simple moving average of $223.97.50-day average above the 200-day ›
The 50-day average ($214.52) is 4.2% below the 200-day average ($223.97), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 38% of its 52-week range, between $186.76 and $252.00.
HON share price
Pick a period: each tab shows how far HON has moved over it, to the last close.
Today's trading
Where HON sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 7.65 is 77.5% below the Industrials median of 34.0.P/S below the sector median ›
The price-to-sales ratio of 1.75 is 56.2% below the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $8.3B on revenue of $38.1B, a net margin of 21.7%.Beat estimates in most recent reports ›
HON beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for HON.
As of October 17, 2026, HON trades at $211.41, with a market value of $67.00B and a P/E ratio of 7.65.
What the numbers say
CleaRank Financial AI's reading of HON's valuation, growth and risks.
HON's P/E of 7.65 sits 77.5% below the Industrials sector median of 34.0, which marks it as a discount to peers. On sales, the P/S of 1.75 is 56.3% below the sector median of 4.0. The company carries a market value of $67.0B, and its trailing earnings come to $27.51 per share.
HON grew revenue 4.30% in its latest year, a pace that is 7.4 percentage points slower than the Industrials sector median of 11.7%. Margins are solid, with a net margin of 21.58% and an operating margin of 20.25%. Return on equity stands at 46.58%, above the sector median of 17.8%. Debt-to-equity is 1.85.
HON's most recent quarterly report, released on July 23, 2026, showed EPS of $1.95. That beat the $1.82 estimate by 7.14%. Still, the share price slid 1.27% in the first session after the report.
HON has beaten the EPS estimate in all 8 of its recent reports; even so, 7 of those 8 beats were followed by a lower share price the next session. The consensus EPS estimate stands at $8.30 for this fiscal year and $9.84 for next, a decline of 57.6% for the current year.
HON's price typically moves 1.03% on a given day, based on the 30-day standard deviation of its daily returns. For as long as the price remains under both moving averages, the downtrend carries risk of its own. The price is 16.11% under its 52-week high of $252.00. Insider sales over the last 18 months totalled $20.7M, and no open-market purchases were made. Planned sales and sales to cover tax on vesting shares are the usual explanation, which makes selling a weaker signal than buying.
HON against the Industrials sector
How HON compares with the median Industrials stock CleaRank tracks.
Price to earnings vs sector: HON trades at a notable discount to sector peers (-77%), which may indicate undervaluation or specific company headwinds.
Return vs XLI: Since May 6, 2025, HON has gained 6.9% against a gain of 25.6% for XLI.
Performance against XLI
HON and the Industrials sector fund over the same days.
Revenue and earnings
How much HON sells, and how much of it becomes profit.
Revenue growth: Revenue fell 2.7% in FY2025 to $37.4B, from $38.5B a year earlier.
Profit margin: The net margin was 12.7% in FY2025, down from 14.9% the year before.
Profitable: HON earned $4.8B in FY2025.
Earnings reality check
Did HON beat what analysts expected, and how did the stock react?
Earnings record: HON beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 7 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $1.82 | $1.95 | +7.14% | -1.27% | -1.77% |
| Apr 23, 2026after close | $4.64 | $4.90 | +5.60% | -0.55% | +0.00% |
| Jan 29, 2026after close | $5.07 | $5.18 | +2.17% | +0.12% | +2.91% |
| Oct 23, 2025after close | $5.13 | $5.64 | +9.94% | -2.05% | -3.79% |
| Jul 24, 2025after close | $5.32 | $5.50 | +3.38% | -0.11% | -0.95% |
| Apr 29, 2025after close | $4.42 | $5.02 | +13.57% | -0.47% | -0.74% |
| Feb 6, 2025after close | $4.69 | $4.94 | +5.33% | -2.05% | -2.17% |
| Oct 24, 2024after close | $5.01 | $5.16 | +2.99% | -0.53% | -1.64% |
As of October 17, 2026, HON has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 7 of those beats; its latest report, on July 23, 2026, came in 7.14% above the estimate and the stock moved -1.27% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 50.9, in neutral territory.RSI above 50 ›
An RSI of 50.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of HON
The score, the reasoning behind it, and what could move the price next.
HON is trading at $211.41, beneath both of its principal moving averages. The price sits 1.45% below the 50-day average of $214.52 and 5.61% below the 200-day average of $223.97. Those two averages point the same way, with the 50-day 4.22% below the 200-day. Within its 52-week range, running from $186.76 up to $252.00, the price stands at 38%.
Short-term and long-term signals disagree. Over the past month the price climbed 1.81%, but over three months it slid 6.05%, and over the past year it gained 10.40%. In the latest session the price moved up 0.43% on volume that ran 30.9% above its average. Momentum is balanced: the 14-day RSI sits at 50.9, in the neutral zone, and the MACD line is negative.
Earnings beat ›
The July 23, 2026 report beat the EPS estimate by 7.14%, and the share price fell 1.27% in the first session after it.
Source: Earnings report, July 23, 2026Rating reaffirmed ›
JP Morgan kept its Overweight rating on October 9, 2026.
Source: Analyst action, JP Morgan, October 9, 2026
New analyst coverage ›
Wells Fargo started coverage at Equal-Weight on September 25, 2026.
Source: Analyst action, Wells Fargo, September 25, 2026
- The two closest levels to watch are the 50-day SMA at $214.52, which sits above the price, and the 20-day EMA at $210.21, which sits below it.
- The 14-day RSI is 50.9, which falls in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 signal stretched momentum.
- Following the July 23, 2026 report, the share price dropped 1.27% in the first session. Over the last 8 reports, HON has beaten estimates in 8 of 8.
HON stays in a downtrend while it trades below both its 50-day average of $214.52 and its 200-day average of $223.97. A close back above the 50-day would mark the first sign of repair. Until then, the 50-day SMA at $214.52 is the first hurdle above the price.
To the downside, the first level beneath the price is the 20-day EMA, at $210.21.
Technical indicators
Momentum and trend for HON, from its daily closes.
As of October 17, 2026, with HON at $211.41, its 14-day RSI is 50.9 (neutral territory), its 50-day simple moving average is $214.52 and its 200-day is $223.97.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What HON moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, HON's 1-year correlation of daily returns is +0.48 with S&P 500 (SPY), +0.40 with Nasdaq 100 (QQQ), +0.13 with Bitcoin (BTC) and +0.19 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
14 of 24 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $262.00 is 23.9% above the price.More buy ratings than three months ago ›
14 of 24 rate it a buy now, against 15 of 24 three months ago.
HON Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Maintains | Overweight |
| Sep 25, 2026 | Wells Fargo | Initiates | Equal-Weight |
| Aug 31, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Aug 18, 2026 | RBC Capital | Maintains | Outperform |
| Aug 17, 2026 | Jefferies | Assumes | Hold |
| Aug 14, 2026 | JP Morgan | Maintains | Overweight |
As of October 17, 2026, 24 Wall Street analysts cover HON: 14 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $186.00 to $303.00, with a median of $262.00, 23.9% above the price of $211.41.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
HON trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from HON's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much HON tends to move, against the market and on its own.
The long record
HON's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.03% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 34.0%, from February 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
76% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $41,982, against $42,055 in the S&P 500 (SPY).
HON Drawdowns & Recovery
As of October 17, 2026, HON's worst peak-to-trough fall over the last 10 years with dividends reinvested was -34.0% (February 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 76% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HON in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: HON trailed the S&P 500 over this period: $41,982 against $42,055.
A $10,000 investment in HON in October 2016 would be worth about $41,982 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HON, and which have not.
Strongest month, July: an average of +7.15%, up in 6 of 10 years.
Weakest month, March: an average of -1.91%, up in 5 of 10 years.
This month, October: has averaged +1.27%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, HON's strongest calendar month has been July (average +7.15%, up in 6 of 10 years) and its weakest March (average -1.91%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HON, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HON today could grow to about $19,700 by 2036 in the base case, with a 90th-percentile outcome near $52,196 and a 10th-percentile outcome around $7,435. Projections are statistical simulations, not guarantees.
HON Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $277 for HON by 2030 in the base case, from $211 today (1.3x over 4 years). The 10th-percentile path ends near $150. These are outcomes of a Monte Carlo simulation run on HON's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $166 | $226 | $308 | |
| 2028 | $157 | $242 | $374 | |
| 2029 | $152 | $259 | $442 | |
| 2030 | $150 | $277 | $514 | |
| 2031 | $149 | $297 | $591 |
Method: a lognormal simulation of HON's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
HON insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought HON shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, HON insiders reported 10 open-market sales worth $20.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Kenneth J West
Officer
|
Sell | 316 | $77.6K |
| Jul 31, 2026 | Su Ping Lu
General Counsel
|
Grant | 382 | - |
| Jul 31, 2026 | Jennifer J Reilly
Officer
|
Grant | 747 | - |
| Jul 31, 2026 | Michal Stepniak
Chief Financial Officer
|
Grant | 401 | - |
| Jul 30, 2026 | Su Ping Lu
General Counsel
|
Grant | 471 | - |
| Jul 30, 2026 | Michal Stepniak
Chief Financial Officer
|
Grant | 604 | - |
| Jul 30, 2026 | Kenneth J West
Officer
|
Grant | 403 | - |
| Jul 28, 2026 | Billal Hammoud
Officer
|
Grant | 349 | - |
| Jul 28, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 300 | - |
| Jul 27, 2026 | Kenneth J West
Officer
|
Sell | 17.0K | $4.2M |
| Jul 27, 2026 | Kenneth J West
Officer
|
Option | 17.0K | $3.3M |
| Jul 16, 2026 | Billal Hammoud
Officer
|
Grant | 1.0K | - |
| Jul 16, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 3.1K | - |
| Jul 16, 2026 | Su Ping Lu
General Counsel
|
Grant | 2.0K | - |
| Jul 16, 2026 | James Masso
Officer
|
Grant | 1.9K | - |
| Jul 16, 2026 | Michal Stepniak
Chief Financial Officer
|
Grant | 2.6K | - |
| Jul 16, 2026 | Kenneth J West
Officer
|
Grant | 1.0K | - |
| Jun 1, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 2.0K | - |
| Apr 24, 2026 | Billal Hammoud
Officer
|
Grant | 471 | - |
| Apr 15, 2026 | Duncan B Angove
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Craig Arnold
Director
|
Grant | 359 | - |
| Apr 15, 2026 | William S Ayer
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Kevin M Burke
Director
|
Grant | 625 | - |
| Apr 15, 2026 | D. Scott Davis
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Deborah Flint
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Michael W Lamach
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Grace D Lieblein
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Indra K Nooyi
Director
|
Grant | 256 | - |
| Apr 15, 2026 | Marc Steinberg
Director
|
Grant | 605 | - |
| Apr 15, 2026 | Robin Watson
Director
|
Grant | 625 | - |
| Apr 15, 2026 | Stephen Williamson
Director
|
Grant | 625 | - |
| Mar 2, 2026 | James E Currier
Officer
|
Sell | 2.2K | $547.7K |
| Mar 2, 2026 | Kenneth J West
Officer
|
Sell | 873 | $211.9K |
| Feb 23, 2026 | Grace D Lieblein
Director
|
Sell | 5.8K | $1.4M |
| Feb 23, 2026 | James E Currier
Officer
|
Grant | 834 | - |
| Feb 23, 2026 | Billal Hammoud
President
|
Grant | 1.0K | - |
| Feb 23, 2026 | Grace D Lieblein
Director
|
Option | 7.8K | $1.1M |
| Feb 23, 2026 | Su Ping Lu
General Counsel
|
Grant | 1.1K | - |
| Feb 23, 2026 | Michal Stepniak
Chief Financial Officer
|
Grant | 1.5K | - |
| Feb 23, 2026 | Kenneth J West
Officer
|
Grant | 965 | - |
| Feb 19, 2026 | D. Scott Davis
Director
|
Sell | 2.4K | $568.1K |
| Feb 19, 2026 | D. Scott Davis
Director
|
Option | 3.2K | $372.8K |
| Feb 13, 2026 | James E Currier
Officer
|
Grant | 1.6K | - |
| Feb 13, 2026 | Billal Hammoud
Officer
|
Grant | 698 | - |
| Feb 13, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 6.7K | - |
| Feb 13, 2026 | Karen Mattimore
Officer
|
Grant | 955 | - |
| Feb 13, 2026 | Kenneth J West
Officer
|
Grant | 698 | - |
| Feb 12, 2026 | James E Currier
Chief Executive Officer
|
Grant | 3.2K | - |
| Feb 12, 2026 | Billal Hammoud
Officer
|
Grant | 802 | - |
| Feb 12, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 8.2K | - |
| Feb 12, 2026 | Karen Mattimore
Officer
|
Grant | 1.5K | - |
| Feb 11, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 1.1K | - |
| Feb 11, 2026 | Karen Mattimore
Officer
|
Grant | 529 | - |
| Feb 10, 2026 | Vimal M Kapur
Chief Executive Officer
|
Grant | 2.7K | - |
| Feb 10, 2026 | Robert D Mailloux
Officer
|
Grant | 1.5K | - |
| Feb 10, 2026 | Karen Mattimore
Officer
|
Grant | 878 | - |
| Feb 6, 2026 | Robert D Mailloux
Officer
|
Sell | 5.3K | $1.3M |
| Feb 6, 2026 | Robert D Mailloux
Officer
|
Option | 5.3K | $904.5K |
| Jan 30, 2026 | Robert D Mailloux
Officer
|
Sell | 10.5K | $2.4M |
| Jan 30, 2026 | Robert D Mailloux
Officer
|
Option | 10.5K | $1.7M |
| Dec 16, 2025 | Robert D Mailloux
Officer
|
Grant | 2.9K | - |
| Oct 28, 2025 | Kenneth J West
Officer
|
Grant | 2.3K | - |
| Oct 2, 2025 | Kenneth J West
Officer
|
Grant | 950 | - |
| Aug 27, 2025 | Lucian Boldea
Officer
|
Sell | 42.1K | $9.3M |
| Aug 27, 2025 | Lucian Boldea
Officer
|
Option | 36.2K | $6.7M |
| Aug 1, 2025 | Kenneth J West
Officer
|
Sell | 3.4K | $752.0K |
| Aug 1, 2025 | James E Currier
Officer
|
Grant | 1.4K | - |
| Aug 1, 2025 | Su Ping Lu
General Counsel
|
Grant | 710 | - |
| Aug 1, 2025 | Michal Stepniak
Chief Financial Officer
|
Grant | 745 | - |
| Aug 1, 2025 | Kenneth J West
Officer
|
Option | 2.8K | $477.5K |
| Jul 29, 2025 | Michal Stepniak
Chief Financial Officer
|
Grant | 616 | - |
| Jul 29, 2025 | Kenneth J West
Chief Executive Officer
|
Grant | 635 | - |
| Jul 28, 2025 | Billal Hammoud
Officer
|
Grant | 627 | - |
| Jul 25, 2025 | James E Currier
Officer
|
Grant | 662 | - |
| Jul 25, 2025 | Kenneth J West
Officer
|
Grant | 552 | - |
| May 30, 2025 | Vimal M Kapur
Chief Executive Officer
|
Grant | 1.9K | - |
| Apr 24, 2025 | Billal Hammoud
Officer
|
Grant | 436 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.